Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 160
Filtrer
1.
Dev Cell ; 57(1): 63-79.e8, 2022 01 10.
Article de Anglais | MEDLINE | ID: mdl-34963058

RÉSUMÉ

In all eutherian mammals, growth of the fetus is dependent upon a functional placenta, but whether and how the latter adapts to putative fetal signals is currently unknown. Here, we demonstrate, through fetal, endothelial, hematopoietic, and trophoblast-specific genetic manipulations in the mouse, that endothelial and fetus-derived IGF2 is required for the continuous expansion of the feto-placental microvasculature in late pregnancy. The angiocrine effects of IGF2 on placental microvasculature expansion are mediated, in part, through IGF2R and angiopoietin-Tie2/TEK signaling. Additionally, IGF2 exerts IGF2R-ERK1/2-dependent pro-proliferative and angiogenic effects on primary feto-placental endothelial cells ex vivo. Endothelial and fetus-derived IGF2 also plays an important role in trophoblast morphogenesis, acting through Gcm1 and Synb. Thus, our study reveals a direct role for the imprinted Igf2-Igf2r axis on matching placental development to fetal growth and establishes the principle that hormone-like signals from the fetus play important roles in controlling placental microvasculature and trophoblast morphogenesis.


Sujet(s)
Facteur de croissance IGF-II/métabolisme , Placenta/vascularisation , Récepteur IGF de type 2/métabolisme , Animaux , Lignée cellulaire , Protéines de liaison à l'ADN/génétique , Cellules endothéliales/métabolisme , Femelle , Développement foetal , Foetus/métabolisme , Facteur de croissance IGF-II/génétique , Facteur de croissance IGF-II/physiologie , Souris , Souris de lignée C57BL , Microvaisseaux/métabolisme , Néovascularisation physiologique/physiologie , Placenta/métabolisme , Placenta/physiologie , Placentation , Grossesse , Récepteur IGF de type 2/physiologie , Facteurs de transcription/génétique , Trophoblastes/métabolisme
2.
Elife ; 92020 05 05.
Article de Anglais | MEDLINE | ID: mdl-32369018

RÉSUMÉ

Cation-independent mannose-6-phosphate receptor, also called insulin-like growth factor two receptor (CIM6P/IGF2R), plays important roles in growth and development, but is also extensively expressed in the mature nervous system, particularly in the hippocampus, where its functions are largely unknown. One of its major ligands, IGF2, is critical for long-term memory formation and strengthening. Using CIM6P/IGF2R inhibition in rats and neuron-specific knockdown in mice, here we show that hippocampal CIM6P/IGF2R is necessary for hippocampus-dependent memory consolidation, but dispensable for learning, memory retrieval, and reconsolidation. CIM6P/IGF2R controls the training-induced upregulation of de novo protein synthesis, including increase of Arc, Egr1, and c-Fos proteins, without affecting their mRNA induction. Hippocampal or systemic administration of mannose-6-phosphate, like IGF2, significantly enhances memory retention and persistence in a CIM6P/IGF2R-dependent manner. Thus, hippocampal CIM6P/IGF2R plays a critical role in memory consolidation by controlling the rate of training-regulated protein metabolism and is also a target mechanism for memory enhancement.


Sujet(s)
Consolidation de la mémoire , Récepteur IGF de type 2/physiologie , Animaux , Femelle , Hippocampe/métabolisme , Hippocampe/physiologie , Mâle , Consolidation de la mémoire/physiologie , Mémoire à long terme/physiologie , Rappel mnésique/physiologie , Souris , Neurones/métabolisme , Neurones/physiologie , Test en champ ouvert , Rats , Rat Long-Evans , Récepteur IGF de type 2/métabolisme
3.
Cells ; 8(10)2019 10 06.
Article de Anglais | MEDLINE | ID: mdl-31590432

RÉSUMÉ

When originally discovered, one of the initial observations was that, when all of the insulin peptide was depleted from serum, the vast majority of the insulin activity remained and this was due to a single additional peptide, IGF-II. The IGF-II gene is adjacent to the insulin gene, which is a result of gene duplication, but has evolved to be considerably more complicated. It was one of the first genes recognised to be imprinted and expressed in a parent-of-origin specific manner. The gene codes for IGF-II mRNA, but, in addition, also codes for antisense RNA, long non-coding RNA, and several micro RNA. Recent evidence suggests that each of these have important independent roles in metabolic regulation. It has also become clear that an alternatively spliced form of the insulin receptor may be the principle IGF-II receptor. These recent discoveries have important implications for metabolic disorders and also for cancer, for which there is renewed acknowledgement of the importance of metabolic reprogramming.


Sujet(s)
Diabète/métabolisme , Facteur de croissance IGF-II/physiologie , Tumeurs/métabolisme , Obésité/métabolisme , Animaux , Lignée cellulaire , Régulation de l'expression des gènes , Humains , Facteur de croissance IGF-II/génétique , Souris , Rats , Récepteur IGF de type 2/physiologie
4.
Mol Hum Reprod ; 25(9): 572-585, 2019 09 01.
Article de Anglais | MEDLINE | ID: mdl-31418778

RÉSUMÉ

Fetal growth restriction (FGR) is caused by poor placental development and function early in gestation. It is well known that placentas from women with FGR exhibit reduced cell growth, elevated levels of apoptosis and perturbed expression of the growth factors, cytokines and the homeobox gene family of transcription factors. Previous studies have reported that insulin-like growth factor-2 (IGF2) interacts with its receptor-2 (IGF2R) to regulate villous trophoblast survival and apoptosis. In this study, we hypothesized that human placental IGF2R-mediated homeobox gene expression is altered in FGR and contributes to abnormal trophoblast function. This study was designed to determine the association between IGF2R, homeobox gene expression and cell survival in pregnancies affected by FGR. Third trimester placentas were collected from FGR-affected pregnancies (n = 29) and gestation matched with control pregnancies (n = 30). Functional analyses were then performed in vitro using term placental explants (n = 4) and BeWo trophoblast cells. mRNA expression was determined by real-time PCR, while protein expression was examined by immunoblotting and immunohistochemistry. siRNA transfection was used to silence IGF2R expression in placental explants and the BeWo cell-line. cDNA arrays were used to screen for downstream targets of IGF2R, specifically homeobox gene transcription factors and apoptosis-related genes. Functional effects of silencing IGF2R were then verified by ß-hCG ELISA, caspase activity assays and a real-time electrical cell-impedance assay for differentiation, apoptosis and cell growth potential, respectively. IGF2R expression was significantly decreased in placentas from pregnancies complicated by idiopathic FGR (P < 0.05 versus control). siRNA-mediated IGF2R knockdown in term placental explants and the trophoblast cell line BeWo resulted in altered expression of homeobox gene transcription factors, including increased expression of distal-less homeobox gene 5 (DLX5), and decreased expression of H2.0-Like Homeobox 1 (HLX) (P < 0.05 versus control). Knockdown of IGF2R transcription increased the expression and activity of caspase-6 and caspase-8 in placental explants, decreased BeWo proliferation and increased BeWo differentiation (all P < 0.05 compared to respective controls). This is the first study linking IGF2R placental expression with changes in the expression of homeobox genes that control cellular signalling pathways responsible for increased trophoblast cell apoptosis, which is a characteristic feature of FGR.


Sujet(s)
Apoptose/génétique , Retard de croissance intra-utérin/génétique , Gènes homéotiques , Protéines à homéodomaine/génétique , Placenta/métabolisme , Récepteur IGF de type 2/physiologie , Adulte , Études cas-témoins , Lignée cellulaire , Femelle , Retard de croissance intra-utérin/anatomopathologie , Expression des gènes , Humains , Nouveau-né , Placenta/anatomopathologie , Placentation/génétique , Grossesse
5.
Am J Chin Med ; 43(8): 1567-91, 2015.
Article de Anglais | MEDLINE | ID: mdl-26621443

RÉSUMÉ

IGF-IIR plays important roles as a key regulator in myocardial pathological hypertrophy and apoptosis, which subsequently lead to heart failure. Salvia miltiorrhiza Bunge (Danshen) is a traditional Chinese medicinal herb used to treat cardiovascular diseases. Tanshinone IIA is an active compound in Danshen and is structurally similar to 17[Formula: see text]-estradiol (E[Formula: see text]. However, whether tanshinone IIA improves cardiomyocyte survival in pathological hypertrophy through estrogen receptor (ER) regulation remains unclear. This study investigates the role of ER signaling in mediating the protective effects of tanshinone IIA on IGF-IIR-induced myocardial hypertrophy. Leu27IGF-II (IGF-II analog) was shown in this study to specifically activate IGF-IIR expression and ICI 182,780 (ICI), an ER antagonist used to investigate tanshinone IIA estrogenic activity. We demonstrated that tanshinone IIA significantly enhanced Akt phosphorylation through ER activation to inhibit Leu27IGF-II-induced calcineurin expression and subsequent NFATc3 nuclear translocation to suppress myocardial hypertrophy. Tanshinone IIA reduced the cell size and suppressed ANP and BNP, inhibiting antihypertrophic effects induced by Leu27IGF-II. The cardioprotective properties of tanshinone IIA that inhibit Leu27IGF-II-induced cell hypertrophy and promote cell survival were reversed by ICI. Furthermore, ICI significantly reduced phospho-Akt, Ly294002 (PI3K inhibitor), and PI3K siRNA significantly reduced the tanshinone IIA-induced protective effect. The above results suggest that tanshinone IIA inhibited cardiomyocyte hypertrophy, which was mediated through ER, by activating the PI3K/Akt pathway and inhibiting Leu27IGF-II-induced calcineurin and NFATC3. Tanshinone IIA exerted strong estrogenic activity and therefore represented a novel selective ER modulator that inhibits IGF-IIR signaling to block cardiac hypertrophy.


Sujet(s)
Abiétanes/pharmacologie , Cardiotoniques , Facteur de croissance IGF-II/antagonistes et inhibiteurs , Myocytes cardiaques/anatomopathologie , Protéines proto-oncogènes c-akt/métabolisme , Récepteurs des oestrogènes/métabolisme , Animaux , Calcineurine/métabolisme , Lignée cellulaire , Survie cellulaire/effets des médicaments et des substances chimiques , Oestradiol/analogues et dérivés , Oestradiol/métabolisme , Fulvestrant , Hypertrophie/génétique , Hypertrophie/prévention et contrôle , Facteur de croissance IGF-II/effets indésirables , Myocytes cardiaques/effets des médicaments et des substances chimiques , Facteurs de transcription NFATC/métabolisme , Phytothérapie , Rats , Récepteur IGF de type 2/métabolisme , Récepteur IGF de type 2/physiologie , Récepteurs des oestrogènes/antagonistes et inhibiteurs , Récepteurs des oestrogènes/physiologie , Salvia miltiorrhiza/composition chimique , Transduction du signal/effets des médicaments et des substances chimiques , Transduction du signal/physiologie
6.
J Dairy Sci ; 98(5): 3224-35, 2015 May.
Article de Anglais | MEDLINE | ID: mdl-25747832

RÉSUMÉ

This study investigated the influence of day of gestation (DG) and feeding regimens (FR) on the expression of genes responsible for placenta development, nutrient transfer, and angiogenic factors in Holstein × Gyr cows. Forty pregnant multiparous Holstein × Gyr cows with an average initial body weight of 482±10.8kg and an initial age of 5±0.8 yr were allocated to 1 of 2 FR: ad libitum (AL; n=20) or maintenance level (ML; n=20). Maintenance level was considered to be 1.15% of body weight (dry matter basis) and met 100% of the net energy requirements and AL provided 190% of the total net energy requirements. Cows were slaughtered at 4 DG: 139, 199, 241, and 268d. After the cows were slaughtered, the placenta and uterus were separated and weighed. Caruncles and cotyledons were individually separated, counted, and weighed. Placenta expressed as kilograms and grams per kilogram of empty body weight (EBW) was heavier in ML- than in AL-fed cows at 268d of gestation. Placenta expressed as kilograms and grams per kilogram of EBW was the lightest at 139d of gestation, and the greatest mass was observed at 268d in ML-fed cows. However, in AL-fed cows, the heaviest placenta expressed as grams per kilogram of EBW was observed from 199d of gestation. Placentomes expressed as grams per kilogram of EBW were heavier in ML-fed cows during gestation, and the number of placentomes was greater in ML-fed cows at 268d of gestation. We observed that IGFR1 and IGFR2 were involved in placenta adaptations when ML was provided, as their expression in placentome cells was greater in ML-fed cows at 268d of gestation. The genes responsible for angiogenesis were also greater in ML-fed cows: VEGFA, GUCY1B3, HIFA, FGF2, and NOS3 were altered by FR and DG interaction and they were greater in ML-fed cows at 268d of gestation. In addition, VEGFB and ANGPT2 did not show interactions between FR and DG, but they were greater in ML-fed cows. Thus, we suggest that the placenta from an ML-fed cow develops adaptations to the reduced nutrient supply by altering its structure and gene expression, thereby developing mechanisms for potential increased nutrient transfer efficiency to the fetus.


Sujet(s)
Bovins/physiologie , Régime alimentaire/médecine vétérinaire , Expression des gènes , Âge gestationnel , Placenta/physiologie , Adaptation physiologique , Animaux , Poids , Ration calorique , Femelle , Néovascularisation physiologique/génétique , Besoins nutritifs , Taille d'organe , Placenta/anatomie et histologie , Placenta/métabolisme , Grossesse , Récepteur IGF de type 1/génétique , Récepteur IGF de type 1/physiologie , Récepteur IGF de type 2/génétique , Récepteur IGF de type 2/physiologie , Utérus/anatomie et histologie
7.
Domest Anim Endocrinol ; 45(4): 187-95, 2013 Nov.
Article de Anglais | MEDLINE | ID: mdl-24209503

RÉSUMÉ

Abundance of IGF-2 receptor (IGF2R), FSH receptor (FSHR), and LH receptor (LHCGR) mRNA in granulosa cells (GCs) or theca cells (TCs) or both cells as well as estradiol (E2), progesterone (P4), and androstenedione concentrations in follicular fluid were compared in cows genetically selected (Twinner) or not selected (control) for multiple ovulations and twin births. Cows were slaughtered at day 3 to 4 (day 3) and day 5 to 6 (day 5) of an estrous cycle, and ovaries, follicular fluid, GCs, and TCs were collected. The two largest (F1 and F2) E2-active (EA) and E2-inactive (EI) follicles were selected according to their E2-to-P4 ratio and diameter. Androstenedione levels in EA F1 and F2 follicles were 5-fold greater (P < 0.05) in Twinner cows than in control cows on day 3 but did not differ on day 5. Twinner cows also had greater (P < 0.05) E2 and P4 concentrations, whereas steroid levels in EI follicles did not differ (P > 0.10) between genotypes. In EA F2 follicles, IGF2R levels in GCs were greater (P < 0.05) in control cows than in Twinner cows on day 3 and day 5, whereas IGF2R mRNA in TCs did not differ (P > 0.10). On day 3, FSHR mRNA levels were greater (P < 0.05) in GCs of EA F1 and EI F2 follicles of control cows than of Twinner cows. LH receptor mRNA expression was less in GCs and greater in TCs of EA F2 follicles in control cows than in Twinner cows (P < 0.05). We hypothesize that reduced GC IGF2R expression in F2 follicles of Twinner cows may play a role in the development of 2 or more dominant follicles.


Sujet(s)
Bovins/physiologie , Follicule ovarique/physiologie , Ovulation/physiologie , Grossesse gémellaire/physiologie , Récepteur IGF de type 2/physiologie , Androstènedione/analyse , Animaux , Bovins/génétique , Oestradiol/analyse , Femelle , Liquide folliculaire/composition chimique , Cellules de la granulosa/composition chimique , Humains , Follicule ovarique/composition chimique , Grossesse , Grossesse gémellaire/génétique , Progestérone/analyse , ARN messager/analyse , Récepteur IGF de type 2/génétique , Récepteur FSH/génétique , Récepteur LH/génétique , Sélection génétique , Cellules thécales/composition chimique
8.
Gerontology ; 59(3): 240-9, 2013.
Article de Anglais | MEDLINE | ID: mdl-23257688

RÉSUMÉ

BACKGROUND: Insulin-like growth factor 2 (IGF2) is a protein hormone known to regulate cell proliferation, growth, migration, differentiation and survival. The gene is parentally imprinted in the sense that transcripts are almost exclusively derived from the paternal allele. Loss of imprinting of the IGF2 gene is a recurrent observation in growth disorders that combine overgrowth with a variety of malignant tumours. Moreover, IGF2 has been proposed to play a role in the development of a variety of seemingly unrelated cancers that play an important role in geriatric medicine, e.g., breast cancer, colon cancer and lung cancer. Finally, IGF2 has been implicated in cardiovascular disease, since, for example, IGF2 has been shown to influence the size of atherosclerotic lesions. OBJECTIVE: To summarize current knowledge about IGF2, its interactions with binding proteins and receptors and connections with key diseases. METHODS: The contents of this paper were based on reviews of existing literature within the field. RESULTS: There is a substantial amount of research linking IGF2 to growth disorders, cancer and to a much lesser degree cardiovascular disease. Some of the studies on IGF2 and tumour growth have yielded conflicting results, for instance regarding its effect on apoptosis. CONCLUSION: Today, our knowledge on how IGF2 is composed and interacts with receptors has come a long way. However, there is comparatively little information on how IGF2 affects tumour growth and cardiovascular diseases such as atherosclerosis. Thus, further research will be needed to elucidate the impact of IGF2 on key diseases.


Sujet(s)
Maladie/étiologie , Croissance et développement/physiologie , Facteur de croissance IGF-II/physiologie , Animaux , Maladies cardiovasculaires/étiologie , Femelle , Empreinte génomique , Croissance et développement/génétique , Humains , Protéines de liaison aux IGF/physiologie , Facteur de croissance IGF-II/génétique , Mâle , Souris , Tumeurs/étiologie , Maturation post-traductionnelle des protéines , Récepteur IGF de type 1/physiologie , Récepteur IGF de type 2/physiologie , Récepteur à l'insuline/physiologie , Transduction du signal
9.
Biomed Environ Sci ; 26(12): 979-85, 2013 Dec.
Article de Anglais | MEDLINE | ID: mdl-24393507

RÉSUMÉ

OBJECTIVE: To study the role of insulin-like growth factor II receptor in free silica-induced transdifferentiation of primary rat lung fibroblasts. METHODS: Rat lung fibroblasts and rat alveolar macrophages were cultured. A transdifferentiation model of primary rat lung fibroblasts was induced by free silica. Levels of α-SMA protein, IGF-IIR protein and mRNA were measured by immunocytochemistry, Western blot and RT-PCR, respectively. Lung fibroblasts were treated with Wortmannin. RESULTS: The expression levels of α-SMA and IGF-IIR increased with the increasing free silica concentration and decreased after Wortmannin was used. CONCLUSION: The IGF-IIR plays an important role in free silica-induced transdifferentiation of primary rat lung fibroblasts.


Sujet(s)
Différenciation cellulaire/physiologie , Poumon/effets des médicaments et des substances chimiques , Récepteur IGF de type 2/physiologie , Silice/pharmacologie , Animaux , Séquence nucléotidique , Cellules cultivées , Amorces ADN , Fibroblastes/effets des médicaments et des substances chimiques , Poumon/cytologie , Mâle , ARN messager/génétique , Rats , Rat Sprague-Dawley , Récepteur IGF de type 2/génétique
10.
J Physiol ; 590(21): 5425-37, 2012 Nov 01.
Article de Anglais | MEDLINE | ID: mdl-22930271

RÉSUMÉ

In vitro studies using rat and fetal sheep cardiomyocytes indicate that, in addition to its role as a clearance receptor, the insulin-like growth factor 2 receptor (IGF-2R) can induce cardiomyocyte hypertrophy. In the present study, we have determined the effect of specific activation of the IGF-2R in the heart of the late gestation fetus on cardiomyocyte development. Leu(27)IGF-2, an IGF-2R agonist, was infused into the fetal left circumflex coronary artery for 4 days beginning at 128.1 ± 0.4 days gestation. Ewes were humanely killed at 132.2 ± 1.2 days gestation (term, 150 days). Fetuses were delivered and hearts dissected to isolate the cardiomyocytes and to collect and snap-freeze tissue. Leu(27)IGF-2 infusion into the left circumflex coronary artery of fetal sheep increased the area of binucleated cardiomyocytes in the left, but not the right, ventricle. However, this infusion of Leu(27)IGF-2 did not change fetal weight, heart weight, blood pressure, blood gases or cardiomyocyte proliferation/binucleation. The increase in cardiomyocyte size in the Leu(27)IGF-2-infused group was associated with increased expression of proteins in the Gαs, but not the Gαq, signalling pathway. We concluded that infusion of Leu(27)IGF-2 into the left circumflex coronary artery causes cardiac IGF-2R activation in the left ventricle of the heart, and this stimulates cardiomyocyte hypertrophy in a Gαs-dependent manner.


Sujet(s)
Ventricules cardiaques/anatomopathologie , Myocytes cardiaques/anatomopathologie , Récepteur IGF de type 2/physiologie , Animaux , Apoptose/effets des médicaments et des substances chimiques , Prolifération cellulaire/effets des médicaments et des substances chimiques , Cellules cultivées , Vaisseaux coronaires , Cyclic AMP-Dependent Protein Kinases/physiologie , Foetus , Âge gestationnel , Hypertrophie , Facteur de croissance IGF-II/pharmacologie , Ovis
11.
Front Neuroendocrinol ; 33(3): 230-51, 2012 Aug.
Article de Anglais | MEDLINE | ID: mdl-22710100

RÉSUMÉ

Insulin-like growth factor (IGF) signaling greatly impacts the development and growth of the central nervous system (CNS). IGF-I and IGF-II, two ligands of the IGF system, exert a wide variety of actions both during development and in adulthood, promoting the survival and proliferation of neural cells. The IGFs also influence the growth and maturation of neural cells, augmenting dendritic growth and spine formation, axon outgrowth, synaptogenesis, and myelination. Specific IGF actions, however, likely depend on cell type, developmental stage, and local microenvironmental milieu within the brain. Emerging research also indicates that alterations in IGF signaling likely contribute to the pathogenesis of some neurological disorders. This review summarizes experimental studies and shed light on the critical roles of IGF signaling, as well as its mechanisms, during CNS development.


Sujet(s)
Protéines de liaison aux IGF/physiologie , Facteur de croissance IGF-II/physiologie , Facteur de croissance IGF-I/physiologie , Transduction du signal/physiologie , Animaux , Apoptose/physiologie , Encéphale/malformations , Encéphale/embryologie , Encéphale/métabolisme , Système nerveux central/croissance et développement , Humains , Facteur de croissance IGF-I/biosynthèse , Facteur de croissance IGF-II/biosynthèse , Neurogenèse/physiologie , Neurones , Récepteur IGF de type 1/biosynthèse , Récepteur IGF de type 1/physiologie , Récepteur IGF de type 2/physiologie
12.
J Hepatol ; 57(2): 337-43, 2012 Aug.
Article de Anglais | MEDLINE | ID: mdl-22521359

RÉSUMÉ

BACKGROUND & AIMS: The mannose 6-phosphate/insulin-like growth factor II receptor (M6P/IGF2R), a multifunctional protein, plays a central role in intracellular targeting of lysosomal enzymes and control of insulin-like growth factor II (IGF-II) bioactivity. Importantly, the gene encoding this receptor is frequently inactivated in a wide range of malignant tumors including hepatocellular carcinomas. Thus, M6P/IGF2R is considered a putative liver tumor suppressor. The aim of this study was to establish the impact of the receptor on the invasive properties of liver cells. METHODS: Reconstitution experiments were performed by expression of wild type and mutant M6P/IGF2R in receptor-deficient FRL14 fetal rat liver cells. RNA interference was used to induce M6P/IGF2R downregulation in receptor-positive MIM-1-4 mouse hepatocytes. RESULTS: We show that the M6P/IGF2R status exerts a strong impact on the invasiveness of tumorigenic rodent liver cells. M6P/IGF2R-deficient fetal rat liver cells hypersecrete lysosomal cathepsins and penetrate extracellular matrix barriers in a cathepsin-dependent manner. Forced expression of M6P/IGF2R restores intracellular transport of cathepsins to lysosomes and concomitantly reduces the tumorigenicity and invasive potential of these cells. Conversely, M6P/IGF2R knock-down in receptor-positive mouse hepatocytes causes increased cathepsin secretion as well as enhanced cell motility and invasiveness. We also demonstrate that functional M6P-binding sites are important for the anti-invasive properties of M6P/IGF2R, whereas the capacity to bind IGF-II is dispensable for the anti-invasive activity of the receptor in liver cells. CONCLUSIONS: M6P/IGF2R restricts liver cell invasion by preventing the pericellular action of M6P-modified proteins.


Sujet(s)
Hépatocytes/anatomopathologie , Tumeurs du foie/anatomopathologie , Mannose phosphate/métabolisme , Récepteur IGF de type 2/physiologie , Animaux , Lignée cellulaire , Mouvement cellulaire , Prolifération cellulaire , Humains , Leucine/analogues et dérivés , Leucine/pharmacologie , Lysosomes/enzymologie , Souris , Invasion tumorale , Liaison aux protéines , Rats
13.
Exp Cell Res ; 317(16): 2364-73, 2011 Oct 01.
Article de Anglais | MEDLINE | ID: mdl-21672540

RÉSUMÉ

Endocytosis and transport of bovine liver ß-glucuronidase to lysosomes in human fibroblasts are mediated by two receptors: the well-characterized cation-independent mannose 6-phosphate receptor (IGF-II/Man6PR) and an IGF-II/Man6PR-independent receptor, which recognizes a Ser-Trp*-Ser sequence present on the ligand. The latter receptor was detergent extracted from bovine liver membranes and purified. LC/ESI-MS/MS analysis revealed that this endocytic receptor was annexin VI (AnxA6). Several approaches were used to confirm this finding. First, the binding of bovine ß-glucuronidase to the purified receptor from bovine liver membranes and His-tagged recombinant human AnxA6 protein was confirmed using ligand-blotting assays. Second, western blot analysis using antibodies raised against IGF-II/Man6PR-independent receptor as well as commercial antibodies against AnxA6 confirmed that the receptor and AnxA6 were indeed the same protein. Third, double immunofluorescence experiments in human fibroblasts confirmed a complete colocalization of the bovine ß-glucuronidase and the AnxA6 receptor on the plasma membrane. Lastly, two cell lines were stably transfected with a plasmid containing the cDNA for human AnxA6. In both transfected cell lines, an increase in cell surface AnxA6 and in mannose 6-phosphate-independent endocytosis of bovine ß-glucuronidase was detected. These results indicate that AnxA6 is a novel receptor that mediates the endocytosis of the bovine ß-glucuronidase.


Sujet(s)
Annexine A6/physiologie , Endocytose/physiologie , Glucuronidase/métabolisme , Récepteur IGF de type 2/physiologie , Récepteurs de surface cellulaire/physiologie , Animaux , Annexine A6/analyse , Annexine A6/isolement et purification , Anticorps/immunologie , Anticorps/pharmacologie , Bovins , Lignée cellulaire tumorale , Endocytose/effets des médicaments et des substances chimiques , Cellules épithéliales/physiologie , Fibroblastes/effets des médicaments et des substances chimiques , Fibroblastes/physiologie , Humains , Cellules L (lignée cellulaire) , Foie/composition chimique , Foie/enzymologie , Mannose phosphate/pharmacologie , Spectrométrie de masse , Souris , Liaison aux protéines/physiologie , Récepteurs de surface cellulaire/analyse , Récepteurs de surface cellulaire/isolement et purification , Protéines recombinantes/génétique , Protéines recombinantes/immunologie , Protéines recombinantes/métabolisme , Transfection , Vésicules de transport/métabolisme
14.
Development ; 138(9): 1795-805, 2011 May.
Article de Anglais | MEDLINE | ID: mdl-21429986

RÉSUMÉ

Secreted factors from the epicardium are believed to be important in directing heart ventricular cardiomyocyte proliferation and morphogenesis, although the specific factors involved have not been identified or characterized adequately. We found that IGF2 is the most prominent mitogen made by primary mouse embryonic epicardial cells and by a newly derived immortalized mouse embryonic epicardial cell line called MEC1. In vivo, Igf2 is expressed in the embryonic mouse epicardium during midgestation heart development. Using a whole embryo culture assay in the presence of inhibitors, we confirmed that IGF signaling is required to activate the ERK proliferation pathway in the developing heart, and that the epicardium is required for this response. Global disruption of the Igf2 gene, or conditional disruption of the two IGF receptor genes Igf1r and Insr together in the myocardium, each resulted in a significant decrease in ventricular wall proliferation and in ventricular wall hypoplasia. Ventricular cardiomyocyte proliferation in mutant embryos was restored to normal at E14.5, concurrent with the establishment of coronary circulation. Our results define IGF2 as a previously unexplored epicardial mitogen that is required for normal ventricular chamber development.


Sujet(s)
Prolifération cellulaire , Coeur/embryologie , Facteur de croissance IGF-II/physiologie , Myocytes cardiaques/physiologie , Animaux , Prolifération cellulaire/effets des médicaments et des substances chimiques , Cellules cultivées , Embryon de mammifère , Régulation de l'expression des gènes au cours du développement/effets des médicaments et des substances chimiques , Coeur/effets des médicaments et des substances chimiques , Ventricules cardiaques/cytologie , Ventricules cardiaques/métabolisme , Facteur de croissance IGF-II/génétique , Facteur de croissance IGF-II/métabolisme , Facteur de croissance IGF-II/pharmacologie , Souris , Souris de lignée ICR , Souris transgéniques , Myocarde/métabolisme , Myocytes cardiaques/effets des médicaments et des substances chimiques , Myocytes cardiaques/métabolisme , Petit ARN interférent/pharmacologie , Récepteur IGF de type 2/génétique , Récepteur IGF de type 2/métabolisme , Récepteur IGF de type 2/physiologie , Transduction du signal/effets des médicaments et des substances chimiques , Transduction du signal/génétique , Transduction du signal/physiologie
15.
Biol Reprod ; 84(3): 440-6, 2011 Mar.
Article de Anglais | MEDLINE | ID: mdl-20980691

RÉSUMÉ

Insulin-like growth factor 2 (IGF2) enhances proliferation and survival of human first-trimester cytotrophoblasts (CTB) by signaling through the insulin-like growth factor 1 receptor (IGF1R). However, the role of the IGF2 receptor (IGF2R) in regulating trophoblast kinetics is unclear: It could act as a clearance receptor for trafficking excess ligand to lysosomes for degradation and/or directly mediate IGF2 signaling. We used an IGF2R knockdown strategy in BeWo cells and placental villous explants to investigate trophoblast proliferation and survival in response to stimulation by IGF. Both IGF1 and IGF2 significantly (P < 0.001) increased mitosis and reduced apoptosis in serum-starved BeWo cells. Small interfering RNA (siRNA)-mediated knockdown of IGF2R further enhanced IGF2-stimulated mitosis (P < 0.01), and IGF2-mediated rescue of apoptosis (P < 0.001) in these cells. Leu(27)IGF2, an IGF2 analogue that binds to IGF2R but not IGF1R, also protected IGF2R-expressing BeWo cells from apoptosis but did not increase mitosis. IGF treatment of term placental villous explants with reduced syncytial expression of IGF2R increased CTB proliferation (P < 0.001) and decreased apoptosis (P < 0.01) compared to untreated controls. Moreover, IGF2-mediated rescue of CTB apoptosis was significantly greater than that in tissue with normal IGF2R expression. Leu(27)IGF2 promoted mitogenesis and survival only in explants with intact IGF2R expression. Given that altered CTB turnover is observed in pregnancies complicated by fetal growth restriction, the development of strategies to manipulate the IGF2R signaling axis in the syncytiotrophoblast may provide a therapeutic avenue for treating this condition.


Sujet(s)
Facteur de croissance IGF-II/pharmacologie , Facteur de croissance IGF-II/pharmacocinétique , Placenta/effets des médicaments et des substances chimiques , Récepteur IGF de type 2/physiologie , Trophoblastes/effets des médicaments et des substances chimiques , Protéines adaptatrices de la transduction du signal/métabolisme , Protéines adaptatrices de la transduction du signal/physiologie , Survie cellulaire/effets des médicaments et des substances chimiques , Survie cellulaire/génétique , Cellules cultivées , Femelle , Techniques de knock-down de gènes , Humains , Facteur de croissance IGF-II/métabolisme , Facteur de croissance IGF-II/physiologie , Taux de clairance métabolique , Mitose/effets des médicaments et des substances chimiques , Mitose/génétique , Modèles biologiques , Placenta/métabolisme , Placenta/physiologie , Grossesse , Maturation post-traductionnelle des protéines/physiologie , Petit ARN interférent/pharmacologie , Récepteur IGF de type 2/antagonistes et inhibiteurs , Récepteur IGF de type 2/génétique , Récepteur IGF de type 2/métabolisme , Transfection , Trophoblastes/cytologie , Trophoblastes/métabolisme , Trophoblastes/physiologie
16.
Br J Cancer ; 103(10): 1479-84, 2010 Nov 09.
Article de Anglais | MEDLINE | ID: mdl-20924377

RÉSUMÉ

Insulin-like growth factor (IGF) and insulin (INS) proteins regulate key cellular functions through a complex interacting multi-component molecular network, known as the IGF/INS axis. We describe how dynamic and multilayer interactions give rise to the multifunctional role of the IGF/INS axis. Furthermore, we summarise the importance of the regulatory IGF/INS network in cancer, and discuss the possibilities and limitations of therapies targeting the IGF/INS axis with reference to ongoing clinical trials concerning the blockage of IGF1R in several types of cancer.


Sujet(s)
Homéostasie/physiologie , Insuline/physiologie , Tumeurs/physiopathologie , Somatomédines/physiologie , Acides aminés/métabolisme , Évolution de la maladie , Acides gras/métabolisme , Glucose/métabolisme , Glycogène/métabolisme , Humains , Protéines de liaison aux IGF/physiologie , Tumeurs/génétique , Tumeurs/thérapie , Récepteur IGF de type 2/physiologie , Transduction du signal
17.
Methods Enzymol ; 480: 181-97, 2010.
Article de Anglais | MEDLINE | ID: mdl-20816211

RÉSUMÉ

Quality control of glycoproteins synthesized in the endoplasmic reticulum (ER) is mediated by lectins and molecular chaperones. N-linked Glc(3)Man(9)GlcNAc(2) oligosaccharides attached to the nascent polypeptides are processed and recognized by lectins in the ER. OS-9 and XTP3-B/Erlectin, mannose 6-phosphate receptor homology (MRH) domain-containing lectins in mammals, were recently identified as ER luminal glycoproteins that participate in ER-associated degradation (ERAD) of misfolded proteins. Frontal affinity chromatography (FAC) and cell-surface expressed lectin assay revealed that both OS-9 and XTP3-B recognize high-mannose type N-glycans that lack the terminal mannose on the C branch. Furthermore, these lectins associate with the HRD1-SEL1L ubiquitin ligase complex on the ER membrane. In this chapter, we describe the FAC methods used to analyze the carbohydrate-recognition specificity of OS-9 and methods to examine the interaction and the effect on ERAD of these proteins in vivo. We also discuss the structure and function of OS-9 and XTP3-B, and the effect of these lectins on ERAD.


Sujet(s)
Réticulum endoplasmique/métabolisme , Lectines/composition chimique , Lectines/physiologie , Maturation post-traductionnelle des protéines , Récepteur IGF de type 2/composition chimique , Séquence d'acides aminés , Animaux , Techniques de chimie analytique/méthodes , Humains , Lectines/métabolisme , Mammifères/métabolisme , Modèles biologiques , Données de séquences moléculaires , Phylogenèse , Maturation post-traductionnelle des protéines/physiologie , Structure tertiaire des protéines/physiologie , Récepteur IGF de type 2/métabolisme , Récepteur IGF de type 2/physiologie , Analyse de séquence de protéine/méthodes , Similitude de séquences d'acides aminés
18.
Neuroscience ; 170(3): 722-30, 2010 Oct 27.
Article de Anglais | MEDLINE | ID: mdl-20659530

RÉSUMÉ

Accumulated evidence suggests that the single transmembrane domain insulin-like growth factor-II/mannose 6-phosphate receptor (IGF-II/M6P or IGF-II receptor) plays an important role in the intracellular trafficking of lysosomal enzymes and endocytosis-mediated degradation of insulin like growth factor (IGF-II). However, the role of this receptor in signal transduction following IGF-II binding remains controversial. In the present study, we revealed that Leu(27)IGF-II, an analog which binds preferentially to the IGF-II receptor, can attenuate K(+)-as well as veratridine-evoked GABA release from the adult rat hippocampal formation. Tetrodotoxin failed to alter the effects of Leu(27)IGF-II on GABA release, thus suggesting the lack of involvement of voltage-dependent Na(+) channels. Interestingly, the effect is found to be sensitive to pertussis toxin (PTX), indicating the possible involvement of a Gi/o protein-dependent pathway in mediating the release of GABA from the hippocampal slices. Additionally, Leu(27)IGF-II was found to attenuate GABA release from frontal cortex but not from striatum. These results, together with the evidence that IGF-II receptors are localized on GABAergic neurons, raised the possibility that this receptor, apart from mediating intracellular trafficking, may also be involved in the regulation of endogenous GABA release by acting directly on GABAergic terminals.


Sujet(s)
Cortex cérébral/métabolisme , Hippocampe/métabolisme , Facteur de croissance IGF-II/analogues et dérivés , Récepteur IGF de type 2/physiologie , Acide gamma-amino-butyrique/métabolisme , Animaux , Cortex cérébral/effets des médicaments et des substances chimiques , Corps strié/effets des médicaments et des substances chimiques , Corps strié/métabolisme , Hippocampe/effets des médicaments et des substances chimiques , Facteur de croissance IGF-II/antagonistes et inhibiteurs , Facteur de croissance IGF-II/pharmacologie , Mâle , Toxine pertussique/pharmacologie , Potassium/antagonistes et inhibiteurs , Potassium/pharmacologie , Rats , Rat Sprague-Dawley , Transduction du signal/effets des médicaments et des substances chimiques , Transduction du signal/physiologie , Tétrodotoxine/pharmacologie , Vératridine/antagonistes et inhibiteurs , Vératridine/pharmacologie , Acide gamma-amino-butyrique/physiologie
19.
Int J Cancer ; 124(11): 2559-67, 2009 Jun 01.
Article de Anglais | MEDLINE | ID: mdl-19195023

RÉSUMÉ

The mannose 6-phosphate/insulin-like growth factor II receptor (M6P/IGF2R) mediates biosynthetic sorting and endocytosis of various factors that impinge on the proliferation, migration and invasiveness of tumour cells. The gene encoding M6P/IGF2R is frequently lost or mutated in a wide range of malignant tumours including squamous cell carcinomas. We have previously shown that M6P/IGF2R-deficient SCC-VII murine squamous cell carcinoma cells secrete large amounts of pro-invasive lysosomal proteinases. Furthermore, the formation of mature lysosomes is impaired in SCC-VII cells. To assess the link between M6P/IGF2R status and tumour invasion, we have now generated SCC-VII lines stably transfected with human M6P/IGF2R cDNA. Reconstitution of functional M6P/IGF2R expression in SCC-VII cells strongly improves the intracellular retention of lysosomal proteinases and restores the formation of mature lysosomes. In addition, the presence of heterologous M6P/IGF2R compromises the growth of SCC-VII cells both in vitro and in vivo. Remarkably, M6P/IGF2R expression also reduces the invasive capacity of SCC-VII cells in response to various chemoattractants. These results indicate that the M6P/IGF2R status influences the metastatic propensity of squamous cell carcinomas.


Sujet(s)
Carcinome épidermoïde/anatomopathologie , Récepteur IGF de type 2/physiologie , Animaux , Prolifération cellulaire , Matrice extracellulaire/physiologie , Femelle , Humains , Lysosomes/enzymologie , Souris , Souris SCID , Invasion tumorale , Récepteur IGF de type 2/analyse , Protéines suppresseurs de tumeurs/physiologie , beta-N-Acetylhexosaminidases/métabolisme
20.
Histol Histopathol ; 24(4): 481-92, 2009 04.
Article de Anglais | MEDLINE | ID: mdl-19224451

RÉSUMÉ

The delivery of soluble lysosomal proteins to the lysosomes is dependent primarily on the mannose 6-phosphate receptor (MPR). The MPR has been demonstrated to attain the early endosomes via a process that requires the interaction of its cytosolic domain with the GGA and AP-1 adaptor proteins. Additionally, the MPR can be recycled back to the trans-Golgi network (TGN) through its interaction with the retromer complex. Interestingly, in I-cell disease (ICD), in which the MPR pathway is non-functional, many soluble lysosomal proteins continue to traffic to the lysosomes. This observation led to the discovery that sortilin is responsible for the MPR-independent targeting of the sphingolipid activator proteins (SAPs) and acid sphingomyelinase (ASM). More recently, our laboratory has tested the hypothesis that sortilin is also capable of sorting a variety of cathepsins that exhibit varying degrees of MPR-independent transport. We have demonstrated that the transport of cathepsin D is partially dependent upon sortilin, that cathepsin H requires sortilin, and that cathepsins K and L attain the lysosomes in a sortilin-independent fashion. As a type-1 receptor, sortilin also has numerous cytosolic binding partners. It has been observed that like the MPR, the anterograde trafficking of sortilin and its cargo require both GGAs and AP-1. Similarly, the retrograde recycling pathway of sortilin also involves an interaction with retromer through a YXXphi site in the cytosolic tail of sortilin. In conclusion, the cytosolic domains of sortilin and MPR possess a high degree of functional homology and both receptors share a conserved trafficking mechanism.


Sujet(s)
Protéines adaptatrices du transport vésiculaire/physiologie , Lysosomes/métabolisme , Facteurs d'ADP-ribosylation/métabolisme , Complexe protéique adaptateur 1/métabolisme , Protéines adaptatrices du transport vésiculaire/métabolisme , Animaux , Cathepsine D/métabolisme , Cathepsine H , Cathepsine K , Cathepsine L , Cathepsines/métabolisme , Cysteine endopeptidases/métabolisme , Humains , Hydrolases/métabolisme , Mucolipidoses/métabolisme , Structure tertiaire des protéines , Transport des protéines , Récepteur IGF de type 2/physiologie , Protéines activatrices des sphingolipides/métabolisme , Réseau trans-golgien/métabolisme
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...